The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study
Abstract
Purpose: To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Methods: A nationwide survey was conducted of 567 oncology practices with data extracted from the records of 4,522 patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); CHOP-rituximab (CHOP-R); or cyclophosphamide, mitoxantrone, vincristine, and prednisone (CNOP). The primary outcome was the average RDI for each regimen based on both planned and reference standards. Other assessments included the incidence of febrile neutropenia and patterns of colony-stimulating factor (CSF) use, as well as the average RDI in high-risk subgroups. Results: Dose reductions ≥ 15% occurred in 40% of patients and treatment delays ≥ 7 days occurred in 24% of patients, resulting in 53% and 48% of patients receiving an RDI less than 85% of the minimum six-cycle and National Comprehensive Cancer Network guideline standards, respectively. Reduced RDI was more prevalent in older patients, with 60% of patients older than 60 years receiving RDI less than 85%. Multivariate analysis identified several independent predictors for reduced RDI, including age older than 60 years, advanced disease stage, poor performance status, and no prophylactic CSF use. Age was no longer a significant risk factor in patients who received prophylactic CSF. Conclusion: Patients with aggressive and potentially curable NHL treated with CHOP, CHOP-R, or CNOP frequently receive reduced RDI. Predictive models based on the risk factors identified for reduced RDI should enable the targeted use of appropriate supportive care, facilitating the delivery of full chemotherapy doses on schedule.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149
Self-citationCrawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Self-citationTrillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., Depierre, A., Johnson, P., Decoster, G., Tomita, D., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90376-q · Cited by 543
Lyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 464
Self-citationPettengell, R., Gurney, H., Radford, J., Deakin, D., James, R., Wilkinson, P., Kane, K., Bentley, J., & Crowther, D. (1992) · Blood · doi:10.1182/blood.v80.6.1430.1430 · Cited by 440
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., & Lyman, G. H. (2006) · Cancer · doi:10.1002/cncr.21847 · Cited by 1,176
Self-citationAapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Self-citationKuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
Self-citationTaplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 601
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Self-citationGriggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
Self-citationSedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
Hurria, A., Levit, L. A., Dale, W., Mohile, S. G., Muss, H. B., Fehrenbacher, L., Magnuson, A., Lichtman, S. M., Bruinooge, S. S., Soto-Perez-de-Celis, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0319 · Cited by 419
Hershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., & Jacobson, J. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1242 · Cited by 390
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Lyman, G. H. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0009 · Cited by 383
Self-citationRisk Models for Predicting Chemotherapy-Induced Neutropenia
Lyman, G. H., Lyman, C. H., Agboola, O., & Anc Study Group (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-427 · Cited by 336
Self-citationDelarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70122-0 · Cited by 304
Bland, K. A., Zadravec, K., Landry, T., Weller, S., Meyers, L., & Campbell, K. L. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.005 · Cited by 109
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X., & Wang, X. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1799-1 · Cited by 69
“However, chemotherapy dose reductions and dose delays, as a result of chemotherapy-induced neutropenia, can lead to reduce patient survival [37–39].”
BackgroundWeaver, A., Love, S. B., Larsen, M., Shanyinde, M., Waters, R., Grainger, L., Shearwood, V., Brooks, C., Gibson, O., Young, A. M., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2224-1 · Cited by 30
Metadata
- Authors
- Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., & Fisher, R. I.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-11-01
- Volume
- 22
- Issue
- 21
- Pages
- 4302-4311
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152807596
- Cited by
- 315
- References
- 25
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.